Komori
Share Issuance and Disposal190AChordia Therapeutics Inc.Pharmaceuticals

Notice Regarding the Designation of a Suspension of Exercise of the 10th and 11th Stock Acquisition Rights

The allottee was notified that all remaining exercises of the already-issued Series 10 and Series 11 stock acquisition rights would be suspended for a specified period. This measure is intended to prioritize financing through the Series 12 stock acquisition rights and avoid rapid dilution resulting from the overlapping exercise of both sets of rights.

Worth reading
64In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
6880000
Shares (number of shares subject to exercise suspension)
Wording
Conditional
How definitive the wording is.

Details of issuance or disposal

Designation of a suspension of exercise of stock acquisition rights with exercise price adjustment clauses

Who receives how much

Series 10: 34,400 rights remaining unexercised (3,440,000 shares); Series 11: 34,400 rights remaining unexercised (3,440,000 shares)

株式会社SBI証券 (Series 10 and Series 11 stock acquisition rights)

The lower thin line represents the existing number of shares to which these shares will be added.

Terms of the stock acquisition rights
Number of Stock Acquisition Rights
Series 10: 34,400 rights remaining unexercised; Series 11: 34,400 rights remaining unexercised
Most recent equity financing
Issued on 22 September 2025: Series 10 and Series 11 stock acquisition rights (third-party allotment)
Exercise suspension notification date
24 August 2026
Exercise suspension period
Series 10: from 9 September 2026 through 24 September 2027 (including that date); Series 11: from 9 September 2026 through 25 September 2028 (including that date)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalDesignation of a suspension of exercise of stock acquisition rights with exercise price adjustment clauses
Number of shares to be issued or disposed ofSeries 10: 34,400 rights remaining unexercised (3,440,000 shares); Series 11: 34,400 rights remaining unexercised (3,440,000 shares)
Intended allottee株式会社SBI証券 (Series 10 and Series 11 stock acquisition rights)
Number of Stock Acquisition RightsSeries 10: 34,400 rights remaining unexercised; Series 11: 34,400 rights remaining unexercised
Most recent equity financingIssued on 22 September 2025: Series 10 and Series 11 stock acquisition rights (third-party allotment)
Exercise suspension notification date24 August 2026
Exercise suspension periodSeries 10: from 9 September 2026 through 24 September 2027 (including that date); Series 11: from 9 September 2026 through 25 September 2028 (including that date)
Items this document does not state (23)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidExercise priceExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To avoid rapid dilution resulting from the concurrent exercise of the Series 12 stock acquisition rights and the Series 10 and Series 11 stock acquisition rights, and to prioritize financing through the Series 12 stock acquisition rights. The company states that it is difficult to reasonably estimate when exercise will be completed and that it will consider withdrawing the designation of exercise suspension in light of its funding needs, the financing environment and other circumstances.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Designation of a Suspension of Exercise of the 10th and 11th Stock Acquisition Rights | Chordia Therapeutics Inc. (190A) timely disclosure | Komori